Ningbo NewBay Medical Technology Co., Ltd. (Headquarters in Ningbo, China, CEO: Zhenhai Shen; NewBay), announced that NewBay initiated a Phase I clinical study of the EP4 antagonist AAT-007 (generic name: grapiprant) in the People’s Republic of China (China) on June 4, 2019.  NewBay is a subsidiary of Ningbo Tai Kang Medical Technology Co., Ltd. (Tai Kang) which licensed AT-007 from AskAt Inc. for cancer therapy in China.  This is the first clinical trial of AAT-007 in China targeting cancer. AskAt will receive a milestone payment from Tai Kang in conjunction with the initiation of the study.